Human Genome lupus drug misses extended study goal - BusinessWeek

[INCIID News Feed]

<img alt="" height="1" width="1" />
Human Genome lupus drug misses extended study goal
BusinessWeek
Human Genome Sciences Inc. and GlaxoSmithKline PLC reported a setback Tuesday as study data showed their lupus drug, Benlysta, worked no better than standard treatment after a year and a half. Last year, HGSI and GlaxoSmithKline said two late-stage, ...
Why HGSI Is a Buy, Even After the Benlysta DataMinyanville.com
Human Genome falls on lupus studyMarketWatch
Human Genome Sciences Announces Withdrawal of European Marketing Authorization ...Benzinga
The Pharma Letter
all 12 news articles &raquo;


More...